- Entheon Biomedical Corp. (ENBI) is sponsoring a clinical research study with Heading Health on the electroneurophysiologic effects of ketamine
- The study will use EEG biomarker research to develop Entheon IQ, one of the pillars of Entheon’s efforts in drug development
- Earlier this year, Entheon partnered with Heading Health to advance psychedelic-assisted therapy to treat mental health disorders
- Entheon Biomedical is a biotechnology research and development company
- Entheon Biomedical Corp. (ENBI) is up 1.64 per cent, trading at $0.31 per share
Entheon Biomedical Corp. (ENBI) is sponsoring a clinical research study with Heading Health on the electroneurophysiologic effects of ketamine.
Earlier this year, Entheon partnered with Heading Health to advance psychedelic-assisted therapy to treat mental health disorders.
Heading Health, led by principal investigator Dr. Steve Levine, has created a psychiatric clinic platform that includes Spravato, an FDA-approved ketamine product that is eligible for insurance reimbursement.
Founded in Austin, Texas, Heading Health delivers high-quality, affordable, and accessible mental health care.
Simon Tankel, the co-founder of Heading Health, commented,
“Heading is pleased to further our partnership with Entheon, advancing psychedelic therapeutic research and enhancing patient access to affordable evidence-based treatments.”
Entheon is sponsoring the study in order to gain deeper insight into patients’ electroneurophysiologic response to psychedelic drug treatment.
The study will use EEG biomarker research to develop Entheon IQ, a program designed to create treatment algorithms founded on objective measurements of responses to treatment.
Timothy Ko, CEO of Entheon commented on the research agreement.
“We believe that EEG-based biomarkers will add a necessary element of empiricism to therapies and contribute to personalization and safety with which care is delivered,” he said.
Entheon IQ forms one of the pillars of Entheon’s efforts in drug development, genetics research, and EEG biomarker research, seeking to develop robust treatment algorithms through data analysis.
Entheon Biomedical is a biotechnology research and development company.
Entheon Biomedical Corp. (ENBI) is up 1.64 per cent, trading at $0.31 per share as of 9:38 am ET.